Chemical inhibitors of RCAN2 can exert their effects through various mechanisms, particularly by targeting the calcineurin-NFAT signaling pathway, which is integral to the expression and function of RCAN2. Cyclosporin A is a prominent inhibitor that forms a complex with cyclophilins and in doing so, it inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and nuclear translocation of NFAT, a transcription factor that drives the expression of RCAN2. Similarly, FK506, also known as Tacrolimus, and Ascomycin both create complexes with FKBP12, which effectively inhibits calcineurin and consequently decreases NFAT-mediated RCAN2 expression. Delphinidin and Resveratrol, which are antioxidants, also inhibit calcineurin, but with the added distinction of combating oxidative stress, which may indirectly influence RCAN2 activity. Emodin directly inhibits calcineurin's phosphatase activity, leading to a reduction in NFAT activity and thus inhibiting RCAN2 function.
In addition to these, there are specific peptides like VIVIT and its derivative, 11R-VIVIT, which are designed to selectively disrupt the interaction between NFAT and calcineurin without affecting other substrates of calcineurin, leading to a more targeted inhibition of NFAT-dependent RCAN2 expression. Pimecrolimus, much like FK506 and Ascomycin, binds to FKBP12, and through this interaction, it inhibits calcineurin, which in turn leads to a decrease in RCAN2 expression mediated by NFAT. Halofuginone inhibits the TGF-β/Smad3 pathway, which interacts with the NFAT signaling, potentially resulting in decreased RCAN2 expression. Curcumin also inhibits calcineurin, thereby reducing NFAT's role in RCAN2 expression. These inhibitors, through their actions on the calcineurin-NFAT pathway and related signaling cascades, are capable of effecting functional inhibition of RCAN2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits calcineurin, which in turn reduces the dephosphorylation and activation of the nuclear factor of activated T-cells (NFAT), a transcription factor involved in the expression of RCAN2, thereby inhibiting RCAN2. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 binds to FKBP12, forming a complex that inhibits calcineurin, similarly to Cyclosporin A, leading to decreased NFAT activity and consequently inhibiting RCAN2. | ||||||
NFAT Inhibitor | 249537-73-3 | sc-507480 | 1 mg | $620.00 | ||
This peptide specifically inhibits the interaction between NFAT and calcineurin without affecting other calcineurin-substrate interactions, which would result in a decrease of RCAN2 activity due to less NFAT-mediated expression of RCAN2. | ||||||
Ascomycin | 104987-12-4 | sc-207303B sc-207303 sc-207303A | 1 mg 5 mg 25 mg | $36.00 $173.00 $316.00 | ||
Ascomycin binds to FKBP12, forming a complex that inhibits calcineurin, thus inhibiting the NFAT pathway and indirectly leading to functional inhibition of RCAN2. | ||||||
Pimecrolimus | 137071-32-0 | sc-208172 | 1 mg | $140.00 | 2 | |
Pimecrolimus binds to FKBP12 and inhibits calcineurin, leading to decreased NFAT activity which is necessary for RCAN2 expression, thereby functionally inhibiting RCAN2. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol has been shown to inhibit the phosphatase activity of calcineurin, thereby reducing NFAT activation and indirectly inhibiting RCAN2 expression and function. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin inhibits calcineurin phosphatase activity, which leads to decreased activation of NFAT and subsequent downregulation of RCAN2 expression, resulting in functional inhibition of RCAN2. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
Halofuginone inhibits the TGF-β/Smad3 pathway, which is known to interact with NFAT signaling, thus potentially reducing NFAT-mediated RCAN2 expression and functionally inhibiting RCAN2. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $103.00 $210.00 $6132.00 | 2 | |
Emodin has been found to inhibit calcineurin, which is crucial for the activation of NFAT that drives the expression of RCAN2, thereby functionally inhibiting RCAN2. | ||||||